About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Cholesterol-lowering Drug Bempedoic Acid Reduces LDL Cholesterol in High-risk Patients

by Colleen Fleiss on March 20, 2019 at 3:23 AM
Font : A-A+

Cholesterol-lowering Drug Bempedoic Acid Reduces LDL Cholesterol in High-risk Patients

Investigational drug bempedoic acid in addition to statins was found to lower LDL or bad cholesterol levels after 12 weeks in patients at high risk for a heart attack or stroke, stated new research presented at the American College of Cardiology's 68th Annual Scientific Session.

LDL cholesterol levels in patients who received the investigational drug, known as bempedoic acid, were reduced by 17.4 percent after 12 weeks of treatment and the reduction was sustained at 52 weeks of treatment, compared with patients who received a placebo, with no differences in overall adverse effects, including serious adverse events and muscle-related side effects, said Anne C. Goldberg, MD, professor of medicine at Washington University School of Medicine in St. Louis and lead author of the study.

Advertisement


"These findings--taken together with other recently reported results of large randomized trials of bempedoic acid--indicate that this agent may add to the armamentarium of treatment options for high-risk patients with atherosclerotic cardiovascular disease whose LDL cholesterol remains uncontrolled despite taking a maximally tolerated statin," Goldberg said.

Studies have shown statins to be highly effective at lowering cholesterol levels and reducing the risk of a heart attack or stroke. These drugs work primarily by blocking an enzyme that the liver uses to make cholesterol, but they also inhibit cholesterol production in muscles. Some patients develop muscle pain and must limit the statin dose they take, or in some cases, discontinue taking a statin to avoid this side effect. About 10 percent of patients taking high-dose statins experience muscle pain as a side effect, Goldberg said.
Advertisement

Bempedoic acid also blocks the liver from making cholesterol, but unlike statins it does not block cholesterol production in muscles. For this reason, Goldberg said, researchers think that bempedoic acid may be less likely than statins to cause muscle pain and thus may promote further reduction of LDL cholesterol levels in patients who must limit their statin doses or not take a statin at all because of this adverse effect.

A total of 779 patients were enrolled in the study. Their average age was 64 years and more than 60 percent were men. At study entry, all patients had LDL cholesterol levels of at least 100 mg/dL and were already taking the highest tolerated dose of a statin. A subset of 77 patients was not able to tolerate any dose of a statin.

In addition to ASCVD, 80 percent of the patients had high blood pressure and 30 percent had diabetes. Six percent had an inherited condition, familial hypercholesterolemia, which causes high LDL cholesterol and elevates risk for a heart attack from an early age.

Patients were randomly assigned to take either bempedoic acid 180 mg tablet once a day or an identical placebo tablet once a day as an add-on to the statin they were already taking. Because this was a double-blind study, neither the patients nor their doctors knew which one they received. Two-thirds of the patients received the study drug and one-third took the placebo.

The study's primary endpoint was the percentage change in LDL cholesterol levels after 12 weeks. Patients continued to take the study medications for a year so that researchers could monitor the safety of bempedoic acid and the durability of treatment effects.

At 12 weeks, LDL cholesterol levels had declined to 97.6 mg/dL from an average of 119.4 mg/dL at study entry for patients taking bempedoic acid. Over the same period, LDL cholesterol levels among patients in the placebo group were essentially unchanged (122.8 mg/dL at 12 weeks vs 122.4 at study entry). In the subgroup of patients who were not taking a statin at study entry, LDL cholesterol levels were reduced by 22 percent at 12 weeks.

At one year, patients in the bempedoic acid group had an average LDL cholesterol level of 99.6 mg/dL, while for those in the placebo group the average was 116.9 mg/dL. Major adjudicated cardiovascular events (5-point MACE) were reported by 6.1 percent of patients taking bempedoic acid and by 8.2 percent of those taking the placebo, a non-statistically significant difference, Goldberg said. Rates of worsening diabetes were similar in the two groups.

"The effect of bempedoic acid was durable at one year and we observed no increase in adverse effects from the addition of bempedoic acid to statin therapy," Goldberg said.

Results of a randomized, double-blinded trial involving 2,230 patients, announced in May 2018, found that bempedoic acid reduced LDL cholesterol by 18.1 percent on top of maximally tolerated statin therapy at 12 weeks with no increase in adverse events compared with the placebo arm.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Ways to Manage Stress during COVID-19 Pandemic
Can Adjusting Fatty Acid Intake Improve Mood in Bipolar Disorder Patients?
Insulin Resistance Doubles the Risk of Major Depressive Disorder
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Cholesterol High Cholesterol Drug Toxicity Heart Attack Diet Lifestyle and Heart Disease Body Mass Index Signature Drug Toxicity Cholesterol - The Enigma Chemical Liposuction Heart Attack- Lifestyle Risks 

Recommended Reading
Link between Statins and Vitamin D
Statins, the cholesterol-lowering medications, and vitamin D appear to complement each other's ......
High Cholesterol
High cholesterol level in blood are a risk for heart disease and stroke. They get deposited in the ....
Test Your Knowledge on Statins
Statins are a group of drugs which help lower the blood cholesterol levels. Cholesterol is required ...
Foods to Lower Cholesterol and Heart Disease
Heart diseases are the most common and threatening disease today. It has takes millions of lives ......
Body Mass Index
Body mass index (BMI) is a simple tool that is generally used to estimate the total amount of body f...
Cholesterol
Cholesterol is produced by the body (liver) and is essential for normal body functioning....
Cholesterol - The Enigma Chemical
The word 'Cholesterol' rings danger bells as soon as it is mentioned. This important chemical is im...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Heart Attack
Heart attack is the death of the heart muscle due to loss of blood supply. Heart disease is the lead...
Heart Attack- Lifestyle risks
Heart attack is the death of the heart muscle due to loss of blood supply. Simple guidelines to avoi...
Liposuction
Liposuction is a cosmetic procedure, which is used to suck out the excess or abnormal fat deposition...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use